Skip Navigation

See how we are providing support for your patients during CORONAVIRUS (COVID‑19)

LEARN MORE

For U.S. Healthcare Professionals

See how we are providing support for your patients during CORONAVIRUS (COVID‑19)

LEARN MORE

For U.S. Healthcare Professionals

Patient.

Made for Selectivity
Made for Remission
Made for Now

  • Entyvio works through a gut-selective MOA by specifically binding to the α4β7 integrin and blocking its interaction with MAdCAM-1, which is mainly expressed on gut endothelial cells.1-7
  • Remission was evaluated at Week 52.1 Individual results may vary.
Healthcare professional.

For adult patients with moderately to severely active UC or CD when other therapies have not worked well enough or cannot be tolerated.

The #1 prescribed biologic for bio-naïve UC and CD patients*

*Based on a month to month analysis of Symphony medical and pharmacy claims from July 2020 to August 2022 with “bio-naïve” defined as patients with UC or CD who had no biologic claims in the past 3 years. Biologics include Cimzia® (certolizumab pegol; UCB, Inc., Smyrna, GA), Humira® (adalimumab; AbbVie Inc., North Chicago, IL), Remicade® (infliximab; Janssen Biotech, Inc., Horsham, PA), Stelara® (ustekinumab; Janssen Biotech, Inc., Horsham, PA), Simponi® (golimumab; Janssen Biotech, Inc., Horsham, PA), and infliximab bio-similars. December 2022.

Entyvio (vedolizumab) Combines

Gut Selectivity2-7

Entyvio helps address inflammation where it occurs—the gut.1

Entyvio specifically binds to the α4β7 integrin and blocks the interaction between the α4β7 integrin and MAdCAM-1, which is mainly expressed on the GI tract endothelial cells.

Discover the MOA

Healthcare professional.

and

Long-Term Remission1,8,9

UC and CD patients achieved remission at Week 52 vs placebo in study populations that included bio‑naïve and anti‑TNFα‑
experienced patients.1,8,9

Individual results may vary.

Week 6 and Week 52:

View UC Data

View CD Data

Healthcare professional.

and

Safety DataFor the Long Term1,10,11

Clinical trials evaluated safety in more than 3300 adults (UC, CD, and healthy volunteers).1 A separate open-label study of up to 7 years demonstrated consistent results across safety parameters.1,10,11†

†In a single-arm, open-label extension study of 2243 patients who received Entyvio with a median exposure of 1072 days (range 1 to 3412 days).10,11

View Safety Profile

Healthcare professional.
VARSITY trial.

ONLY ENTYVIO OFFERS RESULTS FROM THE first head-to-
head study of biologics in moderate to severe UC12,13

Entyvio (vedolizumab)

Vs

Humira®‡ (adalimumab)

‡Humira® (AbbVie Inc., North Chicago, IL). For information related to Humira, please see AbbVie.com.

See the study results

Reaching new milestones

Over 265,000 UC and CD patients in the US since the approval of Entyvio®.
35,000 physicians.

Over 35k PHYSICIANS HAVE PRESCRIBED ENTYVIO
in the US since approval§

Over 90% of commercially insured patients have first-line biologic unrestricted commercial coverage.

Over 90% OF COMMERCIALLY INSURED PATIENTS
have first-line biologic unrestricted commercial coverage for Entyvio‖

Check Coverage

§This information is derived from a Symphony database of Entyvio medical and pharmacy claims from June 2014 to preliminary August 2022. October 2022.

||First-line/unrestricted refers to coverage that does not require biologic step-edits. Data regarding current first-line/unrestricted commercial coverage for Entyvio as of September 2022 and derived from Managed Markets Insights & Technology (MMIT). October 2022

References:

  1. Entyvio (vedolizumab) prescribing information. Takeda Pharmaceuticals.
  2. Briskin M, Winsor-Hines D, Shyjan A, et al. Am J Pathol. 1997;151(1):97-110.
  3. Fedyk E, Wyant T, Yang LL, et al. Inflamm Bowel Dis. 2012;18(11):2107-2119.
  4. Soler D, Chapman T, Yang LL, et al. J Pharmacol Exp Ther. 2009;330(3):864-875.
  5. Wyant T, Fedyk E, Abhyankar B. J Crohns Colitis. 2016;10(12):1437-1444.
  6. Wyant T, Leach T, Sankoh S, et al. Gut. 2015;64(1):77-83.
  7. Milch C, Wyant T, Xu J, et al. J Neuroimmunol. 2013;264:123-126.
  8. Feagan BG, Rubin DT, Danese S, et al. Clin Gastroenterol Hepatol. 2017;15(2):229-239.
  9. Sands BE, Sandborn WJ, Van Assche G, et al. Inflamm Bowel Dis. 2017;23(1):97-106.
  10. Loftus EV, Feagan BG, Panaccione R, et al; for the GEMINI LTS study team. Aliment Pharmacol Ther. 2020;00:1-13.
  11. Data on File. Takeda Pharmaceuticals.
  12. Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. N Engl J Med. 2019;381(13):1215-1226.
  13. Macaluso FS, Maida M, Grova M, et al. Therap Adv Gastroenterol. 2021;14:1-11.